8 Indications mapped
8 Trial phases tracked
4 Recruitment statuses visualized
1 At-a-glance competitive view

You Have the Data. You Don't Have the Picture.

ClinicalTrials.gov contains more than 500,000 registered studies. An AI tool will give you paragraphs — missing trials, conflating phases, producing output your CMO and your VP of BD will interpret three different ways. Bracken's analytics team built the bullseye to answer the real questions in a single auditable view: where is the pipeline crowded, where is Phase 1/2 momentum building, and where is recruiting pressure live right now.

2024 vs. 2026: The Same Landscape, Updated

Hover any data point to see trial name, sponsor, NCT ID, and start date. Click legend items to filter by status.

2024 Data
2026 Data
Why comparison matters: Two time points reveal what a single snapshot cannot — directional momentum. Which indications attracted new investment? Which Phase 2 clusters advanced to Phase 3? Where did recruiting activity cool? The delta between two bullseyes is often the most strategically useful output of all.
⚡

Why not just ask AI? A language model produces a paragraph. It cannot produce a verified, auditable view of 80+ trials that a cross-functional team can align on in a single meeting. Every data point here traces to a specific ClinicalTrials.gov record. The interpretation layer is Bracken's.

Four Things a Table Will Never Show You

Where the field is crowded

Dense Phase 3/4 clusters in Pruritis and Rosacea signal late-stage competitive pressure. Late entry requires a strong differentiation story or a different patient population.

Where the next wave is forming

Phase 1 concentration with few completed trials signals emerging interest before the competitive field has hardened. Hidradenitis Suppurativa shows this pattern — a window that will close.

What is about to change

"Active, not recruiting" trials have closed enrollment and are approaching data readout. Their results will reshape partnership values and regulatory precedent within 12 to 24 months.

Where there is room to move

Thin sectors in indications with known disease burden represent potential white space — or a signal that sponsors have tried and retreated. Knowing which requires the next layer of Bracken analysis.

Built for Any Therapeutic Area

The bullseye is a polar chart — indications around the circumference, trial phases along the radius, recruitment status encoded by shape and color. Bracken has applied this framework across oncology, rare disease, neuroscience, radiopharma, musculoskeletal, and cardiovascular spaces. Because the process is systematized, turnaround is fast and the output stays current as the landscape evolves.

Define scope and extract data

Bracken's consultants define the therapeutic area and indication set, then query ClinicalTrials.gov programmatically — deduplicating, normalizing phases, and mapping indications before visualization begins.

Encode into the polar layout

Each trial becomes a data point positioned by indication and phase. Recruitment status is encoded by shape — circles for completed, squares for recruiting, diamonds for not-yet-recruiting, triangles for active but closed.

Layer in consulting interpretation

The visualization is not the deliverable — the interpretation is. Bracken's consultants annotate the bullseye with strategic observations about competitive density, white space, and near-term data readouts specific to your program.

Common Questions

A clinical trial landscape analysis is a systematic review of all active, completed, and planned clinical trials in a given therapeutic area — typically drawn from ClinicalTrials.gov and supplemented with proprietary intelligence. It maps the competitive environment by phase, indication, and trial status, helping sponsors understand where the pipeline is crowded, where gaps exist, and where differentiation opportunities are greatest.

A bullseye polar chart arranges data points radially around a central axis, making it ideal for comparing multiple categories simultaneously. Applied to clinical trial data, it maps therapeutic indications around the circumference and trial phases along the radius — allowing viewers to immediately see where activity is concentrated, which phases are most crowded, and which indications have early-phase momentum without Phase 3 activity yet.

A well-constructed pipeline visualization can reveal which indications are approaching Phase 3 saturation (signaling competitive pressure), which early-phase clusters suggest emerging scientific interest, where recruiting trials indicate near-term data readouts, and which disease areas have unmet need with limited current clinical activity. This intelligence informs BD strategy, partnership decisions, trial design differentiation, and investor narrative development.

ClinicalTrials.gov returns a table of individual records — useful for detailed lookup but impossible to interpret at a portfolio or landscape level. Bracken's bullseye approach aggregates, normalizes, and visualizes that data so competitive density, phase distribution, and indication-level momentum become immediately visible. The difference is between a spreadsheet and a map: both contain the same data, but only one lets you navigate.

AI tools can generate landscape summaries, but they produce text — not auditable, spatially organized visuals that cross-functional teams can align on. Language models also hallucinate trial details, conflate phases, and cannot guarantee complete coverage of registered studies. Bracken's bullseye is built from direct, programmatic extraction of ClinicalTrials.gov data, with every data point traceable to a source record.

Bracken's process combines structured data extraction from ClinicalTrials.gov with proprietary analytics tooling and consulting judgment. The team identifies the relevant therapeutic area and indication set, queries and cleans trial data, categorizes trials by phase and recruitment status, and renders the output as a polar bullseye chart — readable at a glance by both clinical and commercial audiences.

CONTACT US

Consult with our team.

We would be delighted to discuss your goals and share our services.